Case Study: Cleveland BioLabs and SynCo Bio Partners huddle on a second shot at a defense contract

Posted: 10/03/2008

CLEVELAND BIOLABS (CBL) is a typical virtual biopharmaceutical firm. With a cancer therapy in Phase II clinical trials, and a radiation protection and mitigation drug currently before the Department of Defense, it employs a network of contract service firms around the world. That a company started in Cleveland does basic research at a cancer institute near its headquarters in Buffalo, while managing development in Chicago indicates that geography is flexible in the virtual pharma world.

Another indication of that flexibility is CBL's contract with SynCo Bio Partners, based in Amsterdam. SynCo is conducting process development and manufacturing to current Good Manufacturing Practice (cGMP) standards on Protectan CBLB502, CBL's recombinant protein treatment for radiation. CBL selected SynCo, a small bioprocessing specialist, over two major contractors with U.S. operations: Cambrex's biopharma division, now a part of Lonza, and Diosynth.

Read Full Article